CL2008001136A1 - Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida, en forma de hidrato, solvato, base o sal de adicion a un acido, para preparar un medicamento util en el tratamiento de trastornos motores asociados a la enfermedad de parkinson, tales como, bradiquinesia, discapacidad al caminar y disfagia. - Google Patents

Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida, en forma de hidrato, solvato, base o sal de adicion a un acido, para preparar un medicamento util en el tratamiento de trastornos motores asociados a la enfermedad de parkinson, tales como, bradiquinesia, discapacidad al caminar y disfagia.

Info

Publication number
CL2008001136A1
CL2008001136A1 CL2008001136A CL2008001136A CL2008001136A1 CL 2008001136 A1 CL2008001136 A1 CL 2008001136A1 CL 2008001136 A CL2008001136 A CL 2008001136A CL 2008001136 A CL2008001136 A CL 2008001136A CL 2008001136 A1 CL2008001136 A1 CL 2008001136A1
Authority
CL
Chile
Prior art keywords
pyridin
bradykinesia
dysphagia
oxido
carboxamide
Prior art date
Application number
CL2008001136A
Other languages
English (en)
Spanish (es)
Inventor
Philippe Delay-Goyet
Trillou Christine Ravinet
Claire Delgorge
Gilles Poughon
Christine Menet
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2008001136A1 publication Critical patent/CL2008001136A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CL2008001136A 2007-04-19 2008-04-18 Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida, en forma de hidrato, solvato, base o sal de adicion a un acido, para preparar un medicamento util en el tratamiento de trastornos motores asociados a la enfermedad de parkinson, tales como, bradiquinesia, discapacidad al caminar y disfagia. CL2008001136A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
CL2008001136A1 true CL2008001136A1 (es) 2009-01-16

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001136A CL2008001136A1 (es) 2007-04-19 2008-04-18 Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida, en forma de hidrato, solvato, base o sal de adicion a un acido, para preparar un medicamento util en el tratamiento de trastornos motores asociados a la enfermedad de parkinson, tales como, bradiquinesia, discapacidad al caminar y disfagia.

Country Status (33)

Country Link
US (1) US20100130554A1 (OSRAM)
EP (1) EP2146714B1 (OSRAM)
JP (1) JP5386478B2 (OSRAM)
KR (2) KR101503942B1 (OSRAM)
CN (1) CN101663035B (OSRAM)
AR (1) AR066108A1 (OSRAM)
AT (1) ATE513548T1 (OSRAM)
AU (1) AU2008257322B2 (OSRAM)
BR (1) BRPI0810444A2 (OSRAM)
CA (1) CA2684174C (OSRAM)
CL (1) CL2008001136A1 (OSRAM)
CY (1) CY1111840T1 (OSRAM)
DK (1) DK2146714T3 (OSRAM)
EA (1) EA019194B1 (OSRAM)
ES (1) ES2367408T3 (OSRAM)
FR (1) FR2915100B1 (OSRAM)
HR (1) HRP20110666T1 (OSRAM)
IL (1) IL201448A (OSRAM)
JO (1) JO2678B1 (OSRAM)
MA (1) MA31367B1 (OSRAM)
ME (1) ME00935B (OSRAM)
MX (1) MX2009011284A (OSRAM)
MY (1) MY148092A (OSRAM)
NZ (1) NZ580482A (OSRAM)
PA (1) PA8776801A1 (OSRAM)
PL (1) PL2146714T3 (OSRAM)
PT (1) PT2146714E (OSRAM)
RS (1) RS51869B (OSRAM)
SI (1) SI2146714T1 (OSRAM)
TW (1) TWI439269B (OSRAM)
UY (1) UY31035A1 (OSRAM)
WO (1) WO2008145841A1 (OSRAM)
ZA (1) ZA200907251B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500094A (ja) * 2012-11-28 2016-01-07 サノフイ ４−（シクロプロピルメトキシ）−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−メトキシピリジン−２−カルボキサミドの結晶形態の製造方法およびその結晶形態
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物
US20250120957A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
JP3775685B2 (ja) * 1993-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド Ｐｄｅ▲ｉｖ▼およびｔｎｆ抑制剤としての化合物
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
JP2005538972A (ja) * 2002-07-02 2005-12-22 メルク フロスト カナダ アンド カンパニー ジアリール置換エタンピリドンｐｄｅ４阻害剤
ES2362484T3 (es) * 2003-03-12 2011-07-06 Celgene Corporation Compuestos de ácido n-alquil-hidroxámico-isoindolilo y sus usos farmacéuticos.
AU2006257863A1 (en) * 2005-06-10 2006-12-21 F. Hoffmann-La Roche Ag Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
EA019194B1 (ru) 2014-01-30
KR20150004885A (ko) 2015-01-13
NZ580482A (en) 2011-10-28
DK2146714T3 (da) 2011-10-10
AU2008257322A1 (en) 2008-12-04
EA200970970A1 (ru) 2010-02-26
BRPI0810444A2 (pt) 2016-05-31
JP5386478B2 (ja) 2014-01-15
FR2915100B1 (fr) 2009-06-05
KR101503942B1 (ko) 2015-03-18
CA2684174C (fr) 2014-02-25
EP2146714A1 (fr) 2010-01-27
KR20090130059A (ko) 2009-12-17
WO2008145841A1 (fr) 2008-12-04
AU2008257322B2 (en) 2013-06-13
MA31367B1 (fr) 2010-05-03
RS51869B (sr) 2012-02-29
MY148092A (en) 2013-02-28
JP2010524906A (ja) 2010-07-22
PT2146714E (pt) 2011-09-02
AR066108A1 (es) 2009-07-22
PA8776801A1 (es) 2008-11-19
IL201448A0 (en) 2010-05-31
TWI439269B (zh) 2014-06-01
HRP20110666T1 (hr) 2011-10-31
FR2915100A1 (fr) 2008-10-24
CA2684174A1 (fr) 2008-12-04
JO2678B1 (en) 2013-03-03
ATE513548T1 (de) 2011-07-15
SI2146714T1 (sl) 2011-10-28
ZA200907251B (en) 2011-04-28
UY31035A1 (es) 2008-11-28
ME00935B (me) 2012-06-20
US20100130554A1 (en) 2010-05-27
TW200911247A (en) 2009-03-16
CN101663035A (zh) 2010-03-03
MX2009011284A (es) 2009-11-02
CY1111840T1 (el) 2015-10-07
HK1141725A1 (en) 2010-11-19
EP2146714B1 (fr) 2011-06-22
PL2146714T3 (pl) 2011-10-31
ES2367408T3 (es) 2011-11-03
IL201448A (en) 2014-08-31
CN101663035B (zh) 2012-06-20

Similar Documents

Publication Publication Date Title
MX384234B (es) Uso de pridopidina para el tratamiento de enfermedad de huntington.
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
JP2015532296A5 (OSRAM)
UA107112C2 (uk) Активатори розчинної гуанілатциклази
JP2013014622A5 (OSRAM)
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112013016862A2 (pt) combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
BR112014003704A2 (pt) moduladores ror gama
BR112013020265A2 (pt) formas de rifaximina e uso das mesmas
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
CL2014002847A1 (es) Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras.
CO6430429A2 (es) Aplicaciones terapéuticas de derivados de quinazolinodiona
BR112014031360A2 (pt) derivado de metil amina cíclica heteroaromática
CL2012003212A1 (es) Formas cristalinas i y ii de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado; procedimientos de preparacion; composicion farmaceutica; su procedimiento de preparacion; y su uso para el tratamiento de trastornos tales como trastorno por deficit de atencion y enfermedad de parkinson.
CY1125225T1 (el) 6-μελεις αζα-ετεροκυκλοι που περιεχουν eνωσεις τροποποιησης υποδοχεα δελτα-οπιοειδων, μεθοδοι χρησης και δημιουργιας αυτων
JP2014509653A5 (OSRAM)
BR112014029478A8 (pt) compostos, fármacos de aminoácido contendo flúor e uso destes
CL2013002424A1 (es) Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras.
CL2008001136A1 (es) Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida, en forma de hidrato, solvato, base o sal de adicion a un acido, para preparar un medicamento util en el tratamiento de trastornos motores asociados a la enfermedad de parkinson, tales como, bradiquinesia, discapacidad al caminar y disfagia.